Tadalafil for the Treatment of Raynaud's

Completed · Not applicable · Has a placebo group

Conditions studied: Raynaud

In brief

The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.

Key facts

Study ID

NCT00822354

Run by

Northwestern University

People needed

10

Starts

2008-09-01

Expected to finish

2010-04-01

Last updated by the study team

2014-12-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• active Raynaud's Phenomenon
• stable disease and medication requirements over the previous 2 months
• subjects willing and able to participate in study assessments
• ability to understand and sign informed consent
• ages 18 to 65, both sexes
• a diagnosis of diffuse or limited cutaneous sclerosis, MCTD using the American College Rheumatology criteria

You may not qualify if…

• uncontrolled HTN, DM, unstable disease, angina or using oral nitrates
• smoking, active alcoholism, drug abuse within 5 years
• abnormal renal function
• ulnar arterial occlusive disease as shown by a positive Allen Test
• Pregnant or breast feeding or considering preg. in next 4 months
• past or present major psych. illness
• allergy or sensitivity to tadalafil
• subject unable to understand protocol or give informed consent
• part. in another study trial within 30 days
• taking sildenafil

Where it is running

• Northwestern University Feinberg School of Medicine, Department of Dermatology — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.